https://orcid.org/0000-0002-5545-6086
References
- Lisonkova S, Sabr Y, Mayer C, et al. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014;124(4):771–781.
- Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008;93(1):260–266.
- Seki H. Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Acta Obstet Gynecol Scand. 2014;93(10):959–964.
- Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. BJOG. 1991;98(7):648–655.
- Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble Fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology. 2004;145(11):4838–4845.
- Walton RB, Reed LC, Estrada SM, et al. Evaluation of sildenafil and tadalafil for reversing constriction of fetal arteries in a human placenta perfusion model. Hypertension. 2018;72(1):167–176.
- Daimon A, Kamiya CA, Iwanaga N, et al. Management of pulmonary vasodilator therapy in three pregnancies with pulmonary arterial hypertension. J Obstet Gynaecol Res. 2017;43(5):935–938.
- Wareing M, Myers JE, O’Hara M, et al. Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. Am J Obstet Gynecol. 2004;190(5):1283–1290.
- Trapani A, Gonçalves LF, Trapani TF, et al. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial. Obstet Gynecol. 2016;128(2):253–259.
- Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280–288.
- Ehmann F, Caneva L, Prasad K, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15(3):201–210.
- Kubo M, Tanaka H, Maki S, et al. Safety and dose-finding trial of tadalafil administered for fetal growth restriction: a phase-1 clinical study. J Obstet Gynaecol Res. 2017;43(7):1159–1168.
- Yoshikawa K, Umekawa T, Maki S, et al. Tadalafil improves L-NG-nitroarginine methyl ester-induced preeclampsia with fetal growth restriction-like symptoms in pregnant mice. Am J Hypertens. 2018;31(1):89–96.
- Tanaka H, Kubo M, Nii M, et al. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. J Obstet Gynaecol Res. 2017;43(7):1205–1208.
- Furuhashi FH, Tanaka H, Kaneda MK, et al. Safety trial of tadalafil administered for the treatment of preeclampsia. J Matern Fetal Neonatal Med. 2020;33(1):167–170.
- Samangaya RA, Mires G, Shennan A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Preg. 2009;28(4):369–382.
- McKinney D, Boyd H, Langager A, et al. The impact of fetal growth restriction on latency in the setting of expectant management of preeclampsia. Am J Obstet Gynecol. 2016;214(3):395.e1–395.e7.
- Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Preg Hypertens. 2014;4(2):105–145.
- Maki S, Tanaka H, Tsuji M, et al. Safety evaluation of tadalafil treatment for fetuses with early-onset growth restriction (TADAFER): results from the phase II trial. J Clin Med. 2019;8(6):856.
- Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24–43.
- Kawaguchi R, Matsumoto K, Akira S, et al. Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition. J Obstet Gynaecol Res. 2019;45(4):766–786.
- Sharp A, Cornforth C, Jackson R, et al. Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. Lancet Child Adolesc Health. 2019;3(3):e2–e3.
- Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
- Tachibana R, Umekawa T, Yoshikawa K, et al. Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions. Sci Rep. 2019;9(1):234.